Array ( [slave_lp] => Array ( [hostname] => 129.80.64.116 [username] => lpe [password] => jhvnaRSw98*#Je [database] => local_pages [dbdriver] => mysqli [dbprefix] => [pconnect] => [db_debug] => [cache_on] => [cachedir] => [char_set] => utf8 [dbcollat] => utf8_general_ci [swap_pre] => [autoinit] => 1 [stricton] => ) ) Array ( [slave_lp] => Array ( [hostname] => 129.80.64.116 [username] => lpe [password] => jhvnaRSw98*#Je [database] => local_pages [dbdriver] => mysqli [dbprefix] => [pconnect] => [db_debug] => [cache_on] => [cachedir] => [char_set] => utf8 [dbcollat] => utf8_general_ci [swap_pre] => [autoinit] => 1 [stricton] => ) ) Array ( [slave_lp] => Array ( [hostname] => 129.80.64.116 [username] => lpe [password] => jhvnaRSw98*#Je [database] => local_pages [dbdriver] => mysqli [dbprefix] => [pconnect] => [db_debug] => [cache_on] => [cachedir] => [char_set] => utf8 [dbcollat] => utf8_general_ci [swap_pre] => [autoinit] => 1 [stricton] => ) ) Array ( [slave_lp] => Array ( [hostname] => 129.80.64.116 [username] => lpe [password] => jhvnaRSw98*#Je [database] => local_pages [dbdriver] => mysqli [dbprefix] => [pconnect] => [db_debug] => [cache_on] => [cachedir] => [char_set] => utf8 [dbcollat] => utf8_general_ci [swap_pre] => [autoinit] => 1 [stricton] => ) )

Takeda announces positive topline results from phase 2 study evaluating mezagitamab (tak-079), a potential best-in-class anti-cd38 monoclonal antibody, for primary immune thrombocytopenia

Osaka, japan & cambridge, mass.--(business wire)--takeda (tse:4502/nyse:tak) today announced positive topline results from a phase 2, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability and efficacy of mezagitamab (tak-079) in patients with persistent or chronic primary immune thrombocytopenia (itp). mezagitamab is a fully human immunoglobulin igg1 monoclonal antibody (mab) with high affinity for cd38 expressing cells (including plasmablasts, plasma cells, nat.
TAK Ratings Summary
TAK Quant Ranking